Document is current
Any future updates will be listed below
-
Authors
Neuenschwander, James
Wilkerson, R. Gentry
Weiner, Scott G.
- License Information
-
More Information
Article History
Received: 19 May 2026
Accepted: 26 May 2026
First Online: 4 June 2026
Declarations
:
: Dr. Wilkerson received research funding from CSL Behring, LLC; Greiner Bio-One North America, Inc.; Vapotherm; Calcimedica, Inc.; Tonix Pharmaceuticals, Inc; Pfizer, Inc.; Beckton Dickinson; Pharming Group N.V.; Asklepion Pharmaceuticals, Inc.; and the National Foundation of Emergency Medicine (NFEM). He is a paid consultant for NFEM. Dr. Neuenschwander. Consultant and/or speaker. ThermoFisher. Janssen. AZ. Fisher & Paykel. Pfizer. Aerogen. Serb. Research funding. Bridgesource. Ownership. Asceptiscope. Dr. Neuenschwander is an Editor for this journal. The peer-review process was entirely managed by the Editor-in-Chief, and the author was not involved in the editorial evaluation or decision-making process for this article. Dr. Weiner. Scientific advisory board. Vertex Pharmaceuticals Inc.
